Investing.com - Vyne Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Vyne Therapeutics announced earnings per share of $-0.160 on revenue of $200K. Analysts polled by Investing.com anticipated EPS of $-0.170 on revenue of $133.33K.
Vyne Therapeutics shares are down 28.35% from the beginning of the year , still down 85.71% from its 52 week high of $1.75 set on Friday, December 10, 2021.
Vyne Therapeutics follows other major Healthcare sector earnings this month
Vyne Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar